nach oben

Erschienen in:

31.03.2023 | Operationen des Dünn- und Dickdarmes | CME

Appendixneoplasien

Was ist zu tun?

verfasst von: PD Dr. med. Safak Gül-Klein, Dr. med. Alexander Arnold, Dr. med. Christian Oberender, Matylda Zofia Kuzinska, Miguel Enrique Alberto Vilchez, PD Dr. med. Martina T. Mogl, Prof. Dr. med. Beate Rau, MBA, FEBS (hon)

Erschienen in: coloproctology | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Zusammenfassung

Tumoren des Blinddarms sind selten; etwa 1 % aller Appendektomien weisen eine Neoplasie auf. Hierbei zählen die neuroendokrinen Tumoren zu den häufigsten Neoplasien. Unter den Entitäten der Appendixneoplasien sind weiterhin zu unterscheiden: das Adenokarzinom der Appendix, das muzinöse Adenokarzinom der Appendix sowie die low-grade muzinöse Neoplasie der Appendix, die im Falle einer Perforation ein Pseudomyxoma peritonei ausbilden kann, und die high-grade muzinöse Neoplasie, die erst neuerdings als separate Entität eingestuft wird. Im vorliegenden Beitrag wird auf die Prognose, Diagnostik, Therapie, Pathologie und Nachsorge der einzelnen Entitäten ausführlich eingegangen.

Stöß C, Nitsche U, Neumann PA et al (2021) Acute appendicitis: trends in surgical treatment—a population-based study of over 800 000 patients. Dtsch Arztebl Int 118(14):244–249. https://doi.org/10.3238/arztebl.m2021.0118CrossRefPubMedPubMedCentral

Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA (2008) Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol 34(2):196–201. https://doi.org/10.1016/j.ejso.2007.04.002CrossRefPubMed

Connor SJ, Hanna GB, Frizelle FA (1998) Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies. Dis Colon Rectum 41(1):75–80. https://doi.org/10.1007/BF02236899CrossRefPubMed

Monsonis B, Zins M, Orliac C et al (2021) Retrospective case-control study to predict a potential underlying appendiceal tumor in an acute appendicitis context based on a CT-scoring system. Eur J Radiol 136:109525. https://doi.org/10.1016/j.ejrad.2021.109525CrossRefPubMed

Hoeffel C, Crema MD, Belkacem A et al (2006) Multi-detector row CT: spectrum of diseases involving the ileocecal area. Radiographics 26(5):1373–1390. https://doi.org/10.1148/rg.265045191CrossRefPubMed

Steele SR, Hull TL, Hyman N, Maykel JA, Read TE, Whitlow CB (2021) The ASCRS textbook of colon and rectal surgery. Springer Nature

Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH (Hrsg) Peritoneal carcinomatosis: principles of management

Mehta SS, Bhatt A, Glehen O (2016) Cytoreductive surgery and peritonectomy procedures. Indian J Surg Oncol 7(2):139–151. https://doi.org/10.1007/s13193-016-0505-5CrossRefPubMedPubMedCentral

Löke DR, Helderman RFCP, Franken NAP et al (2021) Simulating drug penetration during hyperthermic intraperitoneal chemotherapy. Drug Deliv 28(1):145–161. https://doi.org/10.1080/10717544.2020.1862364CrossRefPubMedPubMedCentral

10.

Glehen O, Cotte E, Kusamura S et al (2008) Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. J Surg Oncol 98(4):242–246. https://doi.org/10.1002/jso.21061CrossRefPubMed

11.

Bucher P, Mathe Z, Demirag A, Morel P (2004) Appendix tumors in the era of laparoscopic appendectomy. Surg Endosc 18(7):1063–1066. https://doi.org/10.1007/s00464-003-9255-xCrossRefPubMed

12.

Shaib WL, Goodman M, Chen Z et al (2017) Incidence and survival of appendiceal mucinous neoplasms: a SEER analysis. Am J Clin Oncol 40(6):569–573. https://doi.org/10.1097/COC.0000000000000210CrossRefPubMed

13.

Kameda T, Kawai F, Taniguchi N, Omoto K, Kobori Y, Arakawa K (2001) Evaluation of whether the ultrasonographic onion skin sign is specific for the diagnosis of an appendiceal mucocele. J Med Ultrason 41(4):439–443. https://doi.org/10.1007/s10396-014-0527-yCrossRef

14.

Caspi B, Cassif E, Auslender R, Herman A, Hagay Z, Appelman Z (2004) The onion skin sign: a specific sonographic marker of appendiceal mucocele. J Ultrasound Med 23(1):117–121. https://doi.org/10.7863/jum.2004.23.1.117 (quiz 122–3)CrossRefPubMed

15.

Carmignani CP, Hampton R, Sugarbaker CE, Chang D, Sugarbaker PH (2004) Utility of CEA and CA 19‑9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. J Surg Oncol 87(4):162–166. https://doi.org/10.1002/jso.20107CrossRefPubMed

16.

McDonald JR, O’Dwyer ST, Rout S et al (2012) Classification of and cytoreductive surgery for low-grade appendiceal mucinous neoplasms. Br J Surg 99(7):987–992. https://doi.org/10.1002/bjs.8739CrossRefPubMed

17.

Guaglio M, Sinukumar S, Kusamura S et al (2018) Clinical surveillance after macroscopically complete surgery for low-grade appendiceal mucinous neoplasms (LAMN) with or without limited peritoneal spread: long-term results in a prospective series. Ann Surg Oncol 25(4):878–884. https://doi.org/10.1245/s10434-018-6341-9CrossRefPubMed

18.

González-Moreno S, Sugarbaker PH (2004) Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg 91(3):304–311. https://doi.org/10.1002/bjs.4393CrossRefPubMed

19.

Foster JM, Sleightholm RL, Wahlmeier S, Loggie B, Sharma P, Patel A (2016) Early identification of DPAM in at-risk low-grade appendiceal mucinous neoplasm patients: a new approach to surveillance for peritoneal metastasis. World J Surg Oncol 14(1):243. https://doi.org/10.1186/s12957-016-0996-0CrossRefPubMedPubMedCentral

20.

Nikiforchin A, King MC, Baron E et al (2020) Impact of mucin cellularity and distribution on survival in newly diagnosed patients with low-grade appendiceal mucinous neoplasm treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 27(13):4908–4917. https://doi.org/10.1245/s10434-020-08535-1CrossRefPubMed

21.

Roxburgh CS, Fenig YM, Cercek A et al (2019) Outcomes of low-grade appendiceal mucinous neoplasms with remote acellular mucinous peritoneal deposits. Ann Surg Oncol 26(1):118–124. https://doi.org/10.1245/s10434-018-7003-7CrossRefPubMed

22.

González-Moreno S, Brun E, Sugarbaker PH (2005) Lymph node metastasis in epithelial malignancies of the appendix with peritoneal dissemination does not reduce survival in patients treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy. Ann Surg Oncol 12(1):72–80. https://doi.org/10.1007/s10434-004-1161-5CrossRefPubMed

23.

Govaerts K, Lurvink RJ, De Hingh I et al (2021) Appendiceal tumours and pseudomyxoma peritonei: literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. Eur J Surg Oncol 47(1):11–35. https://doi.org/10.1016/j.ejso.2020.02.012CrossRefPubMed

24.

Köhler F, Rosenfeldt M, Matthes N, Kastner C, Germer CT, Wiegering A (2019) Incidental finding of mucinous neoplasia of the appendix : treatment strategies. Chirurg 90(3):194–201. https://doi.org/10.1007/s00104-018-0768-1CrossRefPubMed

25.

Brierley JD, Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumours. John Wiley & Sons

26.

Zauber P, Berman E, Marotta S, Sabbath-Solitare M, Bishop T (2011) Ki-ras gene mutations are invariably present in low-grade mucinous tumors of the vermiform appendix. scand J Gastroenterol 46(7):869–874. https://doi.org/10.3109/00365521.2011.565070CrossRefPubMed

27.

Misdraji J (2015) Mucinous epithelial neoplasms of the appendix and pseudomyxoma peritonei. Mod Pathol 28(1):S67–79. https://doi.org/10.1038/modpathol.2014.129CrossRefPubMed

28.

Tokunaga R, Xiu J, Johnston C et al (2019) Molecular profiling of appendiceal adenocarcinoma and comparison with right-sided and left-sided colorectal cancer. Clin Cancer Res 25(10):3096–3103. https://doi.org/10.1158/1078-0432.Ccr-18-3388CrossRefPubMedPubMedCentral

29.

Chicago Consensus Working Group (2020) The chicago consensus on peritoneal surface malignancies: management of appendiceal neoplasms. Ann Surg Oncol 27(6):1753–1760. https://doi.org/10.1245/s10434-020-08316-wCrossRef

30.

Ward EP, Okamuro L, Khan S et al (2021) Ki67 does not predict recurrence for low-grade appendiceal mucinous neoplasms with peritoneal dissemination after cytoreductive surgery and HIPEC. Hum Pathol 113:104–110. https://doi.org/10.1016/j.humpath.2021.04.007CrossRefPubMed

31.

Yantiss RK, Shia J, Klimstra DS, Hahn HP, Odze RD, Misdraji J (2009) Prognostic significance of localized extra-appendiceal mucin deposition in appendiceal mucinous neoplasms. Am J Surg Pathol 33(2):248–255. https://doi.org/10.1097/PAS.0b013e31817ec31eCrossRefPubMed

32.

Gonzalez RS, Carr NJ, Liao H, Pai RK, Agostini-Vulaj D, Misdraji J (2022) High-grade appendiceal mucinous neoplasm. Arch Pathol Lab Med. https://doi.org/10.5858/arpa.2021-0430-OACrossRefPubMed

33.

Liao X, Vavinskaya V, Sun K et al (2020) Mutation profile of high-grade appendiceal mucinous neoplasm. Histopathology 76(3):461–469. https://doi.org/10.1111/his.13986CrossRefPubMed

34.

Pahlavan PS, Kanthan R (2005) Goblet cell carcinoid of the appendix. World J Surg Oncol 3:36. https://doi.org/10.1186/1477-7819-3-36CrossRefPubMedPubMedCentral

35.

Shannon AB, Goldberg D, Song Y et al (2020) Predictors of lymph node metastases in patients with mucinous appendiceal adenocarcinoma. J Surg Oncol 122(3):399–406. https://doi.org/10.1002/jso.25963CrossRefPubMed

36.

Mehta AM, Bignell MB, Alves S et al (2017) Risk of ovarian involvement in advanced colorectal or appendiceal tumors involving the peritoneum. Dis Colon Rectum 60(7):691–696. https://doi.org/10.1097/DCR.0000000000000791CrossRefPubMed

37.

Taggart MW, Galbincea J, Mansfield PF et al (2013) High-level microsatellite instability in appendiceal carcinomas. Am J Surg Pathol 37(8):1192–1200. https://doi.org/10.1097/PAS.0b013e318282649bCrossRefPubMedPubMedCentral

38.

Asare EA, Compton CC, Hanna NN et al (2016) The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: analysis of the national cancer data base. Cancer 122(2):213–221. https://doi.org/10.1002/cncr.29744CrossRefPubMed

39.

Patrick-Brown TDJH, Carr NJ, Swanson DM, Larsen S, Mohamed F, Flatmark K (2021) Estimating the prevalence of pseudomyxoma peritonei in Europe using a novel statistical method. Ann Surg Oncol 28(1):252–257. https://doi.org/10.1245/s10434-020-08655-8CrossRefPubMed

40.

Pestieau SR, Esquivel J, Sugarbaker PH (2000) Pleural extension of mucinous tumor in patients with pseudomyxoma peritonei syndrome. Ann Surg Oncol 7(3):199–203. https://doi.org/10.1007/bf02523654CrossRefPubMed

41.

Sugarbaker PH (1994) Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. Ann Surg 219(2):109–111. https://doi.org/10.1097/00000658-199402000-00001CrossRefPubMedPubMedCentral

42.

Zissin R, Gayer G, Fishman A, Edelstein E, Shapiro-Feinberg M (2000) Synchronous mucinous tumors of the ovary and the appendix associated with pseudomyxoma peritonei: CT findings. Abdom Imaging 25(3):311–316. https://doi.org/10.1007/s002610000038CrossRefPubMed

43.

Fonseca C, Carvalho S, Cunha TM, Gil RT, Abecasis N (2019) The many faces of pseudomyxoma peritonei: a radiological review based on 30 cases. Radiol Bras 52(6):372–377. https://doi.org/10.1590/0100-3984.2019.0044CrossRefPubMedPubMedCentral

44.

Low RN, Barone RM, Lucero J (2015) Comparison of MRI and CT for predicting the peritoneal cancer index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol 22(5):1708–1715. https://doi.org/10.1245/s10434-014-4041-7CrossRefPubMed

45.

Menassel B, Duclos A, Passot G et al (2016) Preoperative CT and MRI prediction of non-resectability in patients treated for pseudomyxoma peritonei from mucinous appendiceal neoplasms. Eur J Surg Oncol 42(4):558–566. https://doi.org/10.1016/j.ejso.2016.01.005CrossRefPubMed

46.

Baratti D, Kusamura S, Martinetti A et al (2007) Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 14(8):2300–2308. https://doi.org/10.1245/s10434-007-9393-9CrossRefPubMed

47.

Taflampas P, Dayal S, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ (2014) Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal pseudomyxoma peritonei: analysis of 519 patients. Eur J Surg Oncol 40(5):515–520. https://doi.org/10.1016/j.ejso.2013.12.021CrossRefPubMed

48.

Chua TC, Moran BJ, Sugarbaker PH et al (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30(20):2449–2456. https://doi.org/10.1200/JCO.2011.39.7166CrossRefPubMed

49.

Lord AC, Shihab O, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ (2015) Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours. Eur J Surg Oncol 41(3):396–399. https://doi.org/10.1016/j.ejso.2014.08.476CrossRefPubMed

50.

Ahmadi N, Kostadinov D, Sakata S et al (2021) Managing recurrent pseudomyxoma peritonei in 430 patients after complete cytoreduction and HIPEC: a dilemma for patients and surgeons. Ann Surg Oncol 28(12):7809–7820. https://doi.org/10.1245/s10434-021-10093-zCrossRefPubMed

51.

Kusamura S, Barretta F, Yonemura Y et al (2021) The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg 156(3):e206363. https://doi.org/10.1001/jamasurg.2020.6363CrossRefPubMedPubMedCentral

52.

Moran B, Baratti D, Yan TD, Kusamura S, Deraco M (2008) Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol 98(4):277–282. https://doi.org/10.1002/jso.21054CrossRefPubMed

53.

Glehen O, Mohamed F, Sugarbaker PH (2004) Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg 240(2):278–285. https://doi.org/10.1097/01.sla.0000133183.15705.71CrossRefPubMedPubMedCentral

54.

Ronnett BM, Yan H, Kurman RJ, Shmookler BM, Wu L, Sugarbaker PH (2001) Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 92(1):85–91. https://doi.org/10.1002/1097-0142(20010701)92:1〈85::aid-cncr1295〉3.0.co;2‑rCrossRefPubMed

55.

Carr NJ, Cecil TD, Mohamed F et al (2016) A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the peritoneal surface oncology group international (PSOGI) modified Delphi process. Am J Surg Pathol 40(1):14–26. https://doi.org/10.1097/PAS.0000000000000535CrossRefPubMed

56.

Martín-Román L, Lozano P, Gómez Y et al (2021) Which classification system defines best prognosis of mucinous neoplasms of the appendix with peritoneal dissemination: TNM vs PSOGI? J Clin Pathol. https://doi.org/10.1136/jclinpath-2021-207883CrossRefPubMed

57.

WHO Classification of Tumours Editorial Board (2019) WHO classification of tumours. Digestive system tumours: WHO classification of tumours, 1. Aufl. World health organization classification of tumours. World Health Organization

58.

Blackham AU, Swett K, Eng C et al (2014) Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol 109(7):740–745. https://doi.org/10.1002/jso.23547CrossRefPubMed

59.

Mangieri CW, Moaven O, Valenzuela CD et al (2022) Utility of neoadjuvant chemotherapy for peritoneal carcinomatosis secondary to high-grade appendiceal neoplasms for patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 29(4):2641–2648. https://doi.org/10.1245/s10434-021-11153-0CrossRefPubMed

60.

Spiliotis J, Kopanakis N, Efstathiou E et al (2017) Perioperative systemic chemotherapy for peritoneal mucinous appendiceal carcinomas treated with cytoreductive surgery & HIPEC. J BUON 22(3):783–789PubMed

61.

Milovanov V, Sardi A, Ledakis P et al (2015) Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA). Eur J Surg Oncol 41(5):707–712. https://doi.org/10.1016/j.ejso.2015.01.005CrossRefPubMed

62.

Kolla BC, Petersen A, Chengappa M et al (2020) Impact of adjuvant chemotherapy on outcomes in appendiceal cancer. Cancer Med 9(10):3400–3406. https://doi.org/10.1002/cam4.3009CrossRefPubMedPubMedCentral

63.

Choe JH, Overman MJ, Fournier KF et al (2015) Improved survival with anti-VEGF therapy in the treatment of unresectable appendiceal epithelial neoplasms. Ann Surg Oncol 22(8):2578–2584. https://doi.org/10.1245/s10434-014-4335-9CrossRefPubMed

64.

Govaerts K, Chandrakumaran K, Carr NJ et al (2018) Single centre guidelines for radiological follow-up based on 775 patients treated by cytoreductive surgery and HIPEC for appendiceal pseudomyxoma peritonei. Eur J Surg Oncol 44(9):1371–1377. https://doi.org/10.1016/j.ejso.2018.06.023CrossRefPubMed

65.

Xu J (2021) Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs). Ther Adv Med Oncol 13:17588359211042689. https://doi.org/10.1177/17588359211042689CrossRefPubMedPubMedCentral

66.

Alkhayyat M, Saleh MA, Coronado W et al (2021) Epidemiology of neuroendocrine tumors of the appendix in the USA: a population-based national study (2014–2019). Ann Gastroenterol 34(5):713–720. https://doi.org/10.20524/aog.2021.0643CrossRefPubMedPubMedCentral

67.

Shaib W, Krishna K, Kim S et al (2016) Appendiceal neuroendocrine, goblet and signet-ring cell tumors: a spectrum of diseases with different patterns of presentation and outcome. Cancer Res Treat 48(2):596–604. https://doi.org/10.4143/crt.2015.029CrossRefPubMed

68.

Alexandraki KI, Kaltsas GA, Grozinsky-Glasberg S, Chatzellis E, Grossman AB (2016) Appendiceal neuroendocrine neoplasms: diagnosis and management. Endocr Relat Cancer 23(1):R27–41. https://doi.org/10.1530/erc-15-0310CrossRefPubMed

69.

Grozinsky-Glasberg S, Thomas D, Strosberg JR et al (2013) Metastatic type 1 gastric carcinoid: a real threat or just a myth? World J Gastroenterol 19(46):8687–8695. https://doi.org/10.3748/wjg.v19.i46.8687CrossRefPubMedPubMedCentral

70.

Stensbøl AB, Krogh J, Holmager P et al (2021) Incidence, clinical presentation and trends in indication for diagnostic work-up of small intestinal and pancreatic neuroendocrine tumors. Diagnostics (Basel). https://doi.org/10.3390/diagnostics11112030CrossRefPubMed

71.

Oberg K, Couvelard A, Delle Fave G et al (2017) ENETS consensus guidelines for standard of care in neuroendocrine tumours: biochemical markers. Neuroendocrinology 105(3):201–211. https://doi.org/10.1159/000472254CrossRefPubMed

72.

Pape UF, Niederle B, Costa F et al (2016) ENETS consensus guidelines for neuroendocrine neoplasms of the appendix (excluding goblet cell carcinomas). Neuroendocrinology 103(2):144–152. https://doi.org/10.1159/000443165CrossRefPubMed

73.

Rinke A, Wiedenmann B, Auernhammer C et al (2018) AWMF S2k-Leitlinie Neuroendokrine Tumore. Thieme, Stuttgart, New York https://doi.org/10.1055/a-0604-2924CrossRef

74.

Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG (2001) Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol 12(9):1295–1300. https://doi.org/10.1023/a:1012272314550CrossRefPubMed

75.

Rindi G, Klimstra DS, Abedi-Ardekani B et al (2018) A common classification framework for neuroendocrine neoplasms: an international agency for research on cancer (IARC) and world health organization (WHO) expert consensus proposal. Mod Pathol 31(12):1770–1786. https://doi.org/10.1038/s41379-018-0110-yCrossRefPubMedPubMedCentral

76.

Benedix F, Reimer A, Gastinger I et al (2010) Primary appendiceal carcinoma—epidemiology, surgery and survival: results of a German multi-center study. Eur J Surg Oncol 36(8):763–771. https://doi.org/10.1016/j.ejso.2010.05.025CrossRefPubMed

Titel: Appendixneoplasien
Was ist zu tun?
verfasst von: PD Dr. med. Safak Gül-Klein
Dr. med. Alexander Arnold
Dr. med. Christian Oberender
Matylda Zofia Kuzinska
Miguel Enrique Alberto Vilchez
PD Dr. med. Martina T. Mogl
Prof. Dr. med. Beate Rau, MBA, FEBS (hon)
Publikationsdatum: 31.03.2023
Verlag: Springer Medizin
Schlagwörter: Operationen des Dünn- und Dickdarmes
Neuroendokrine Tumoren
Appendizitis
Appendektomie
Low-grade muzinöse Neoplasie der Appendix
Low-grade muzinöse Neoplasie der Appendix
Appendizitis
Erschienen in: coloproctology / Ausgabe 2/2023
Print ISSN: 0174-2442
Elektronische ISSN: 1615-6730
DOI: https://doi.org/10.1007/s00053-023-00686-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Appendixneoplasien

Was ist zu tun?

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Riesig, verdreht und ein akuter Notfall

Akute mesenteriale Ischämie – diagnostischer und therapeutischer Algorithmus

Akute mesenteriale Durchblutungsstörung – arterielle Thrombose

Mitteilungen des BCD und der DGK

Nichtokklusive mesenteriale Ischämie

Komplette mesokolische Exzision für das rechtsseitige Kolonkarzinom

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

Update Innere Medizin